Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999 Jul;14(2):15-9.
doi: 10.3904/kjim.1999.14.2.15.

Imipenem-cilastatin versus sulbactam-cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients

O Ozyilkan  1 , U Yalçintaş, S Başkan
Affiliations
Clinical Trial

Imipenem-cilastatin versus sulbactam-cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients

O Ozyilkan et al. Korean J Intern Med. 1999 Jul.

Abstract

The treatment of infectious complications in cancer patients has evolved as a consequence of the developments in the chemotherapy of cancer patients. In this prospective, randomized study, we compared imipenem-cilastatin and sulbactam-cefoperazone with amikacin in the empiric therapy of febrile neutropenic (< 1000/mm3) patients with liquids and solid tumours. Of 30 evaluable episodes, 15 were treated with imipenem-cilastatin and 15 were treated with sulbactam-cefoperazone plus amikacin. 73% of episodes were culture-positive: gram-positive pathogens accounted for 62% of the isolates. Bacteremia was the most frequent site of infection. The initial clinical response rate for both regimens was 60% (p > 0.05). No major adverse effects occurred. This study demonstrated that imipenem-cilastatin monotherapy and combination therapy of sulbactam-cefoperazone plus amikacin were equally effective empiric therapy for febrile granulocytopenic cancer patients.

PubMed Disclaimer

References

    1. Young LS. Infection in cancer patients. In: Haskell CM, editor. Cancer treatment. Philadelphia: Philadelphia W.B. Saunders; 1995. pp. 206–216.
    1. Pizzo AP. Infection in cancer patients. In: Devita VT, Hellman S, Rosenberg SA, editors. Principles and practice of oncology. Philadelphia: J.B. Lippincott Company; 1993. pp. 2292–2338.
    1. Link H, Maschmeyer G, Meyer p, Hiddemann W, Stille W, Helmerking M. Interventional antimicrobial therapy in febrile neutropenic patients. Study Group of the Ehrlich Society for Chemotherapy. Ann Hematology. 1994;69:231–243. - PubMed
    1. Klastersky J. Prevention and treatment of infections related chemotherapy. In: Cvitcovic E, Droz JP, Armand JP, Khoury S, editors. Handbook of chemotherapy in clinical oncology. Paris: F.I.I.S; 1993. pp. 477–481.
    1. Akita H, Sato Y, Iwata S, Nitta Y, Yokota T, Sunkawa K. Bacteriological and clinical studies on meropenem in the pediatric field. Jpn J Antibiotics. 1992;45:744–755. - PubMed

Publication types

MeSH terms